Stock Market Mid Day Recap – AIG, YHOO, MWE, HFC, HEB
Mid day New Recap -AIG, YHOO, MWE, HFC, HEB
American International Group Inc (NYSE:AIG) soared 4.23% to $34.50. The wholly owned subsidiary of American International Group, International Lease Finance Corporation announced that AirAsia X has signed a letter of intent with ILFC for the lease of six Airbus A330-300 aircraft.
The Company announced the completion of a registered public offering of 188,524,590 shares of AIG common stock at par value of $2.50 per share by the U.S. Department of the Treasury as the selling shareholder. Barclays maintained an equalweight rating on the stock and the price target of $31.00.
Yahoo! Inc (NASDAQ:YHOO) decreased 1.70% to $14.86. Stifel Nicolaus lowered the rating on the stock to hold from buy. The rating was lowered as the new chief executive’s move to re-establish the company as a tech leader may result in lower margins and dilutive acquisitions.
Markwest Energy Partners LP (NYSE:MWE) declined 4.11% to $50.58. The Company announced the pricing a public offering of 6,000,000 common units at $50.72 per common unit. The Company has granted the underwriters a 30-day option to purchase up to 900,000 additional common units to cover the underwriters’ sale of additional common units. The Company intends to use the net proceeds from the offering to fund capital expenditure program, for general working capital and for other general partnership purposes.
HollyFrontier Corp (NYSE:HFC) increased 2.42% to $40.55. The Board of Directors declared a special cash dividend of $0.50 per share, payable on September 4, 2012 to holders. The Board of Directors also approved a regular quarterly dividend of $0.15 per share. This dividend will be paid on October 2, 2012 to all holders.
Hemispherx BioPharma Inc (NYSEAMEX: HEB) surged up 9.12% to $0.48. The Company has filed on July 31, 2012 with the U.S. Food and Drug Administration complete response to the FDA’s November 25, 2009 Complete Response Letter in relation to Ampligen’s New Drug Application for Chronic Fatigue Syndrome. The FDA acknowledged in writing receipt of the Company’s August 1, 2012, response.